CHU Grenoble Alpes - Hôpital Michallon

La Tronche 9 trials 3 recruiting

9 Registered trials

3 Currently recruiting

Organisation

CHU Grenoble Alpes - Hôpital Michallon

Location

La Tronche, France

Identifier

ORL-000008311

Address

Boulevard de la Chantourne, 38700, France

Departments

Dermatology
Hématologie
Hepatogastroenterology
Oncologie médicale
ONCOLOGY
Oncology for adults
Ophtalmologie
Pneumology
Radiology
Radiotherapy for pediatrics > 16 years old

Clinical trials at this site (9)

Search interface

ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p… Pending

2024-517285-41-00 Newly diagnosed prostate cancer with pelvic lymph nodes 5
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Patients with DMMR and/or MSI metastatic colorectal can 4
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/o… Recruiting

2024-511862-35-00 Adults with non-contrast-enhancing diffuse brainstem gl 4 2019-07-19
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting

2023-506027-29-00 Children, adolescents and adults with newly diagnosed d 5 2014-10-01
An open-label safety and tolerability clinical trial of PST-611 in dry age-related macular degeneration. Ended

2024-519025-37-00 Dry age-related macular degeneration. 1 2025-06-19
A study in patients with skin cancer Ended

2024-516914-39-00 Metastatic or unresectable melanoma 5 2022-04-27
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended

2024-516201-23-00 Lung Cancer, NSCLC 4 2019-08-26
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc… Ended

2024-515533-15-00 Locally advanced cervical cancer 4